Literature DB >> 8095456

The CD2 and CD28 adhesion molecules induce long-term autocrine proliferation of CD4+ T cells.

R Costello1, C Cerdan, C Pavon, H Brailly, C Hurpin, C Mawas, D Olive.   

Abstract

In vitro human T lymphocyte activation requires two-signal triggering delivered by lectins, phorbol esters or antibodies directed against surface molecules. Stimulation of adhesion molecules by CD2 and/or CD28 antibodies defines alternative activation pathways. Activation by CD2 + CD28 monoclonal antibodies induces high-level, long-lasting and monocyte-independent proliferation of highly purified T cells. Limiting dilution cultures showed that CD28 in association with CD2 or CD3, without addition of exogenous cytokines, induced single-cell proliferation. CD2 + CD28 stimulation induced long-term interleukin (IL)-2-dependent autocrine proliferation of CD4+ T cell clones. We tried to elucidate this long-term proliferation by evaluating cytokine secretion and cytokine dependency. CD28 associated to CD3 or CD2 induced high levels of IL-2, tumor necrosis factor (TNF) and IL-4 secretion for 10 days, in contrast to CD3 alone which induced only TNF secretion. Cytokines of the monocytic lineage were also secreted, such as colony-stimulating factor-1, granulocyte-macrophage colony-stimulating factor or IL-1, the latter being more specific of CD2 + CD28 activation. Blocking antibodies confirmed the crucial role of IL-2 in CD2 + CD28 activation. Anti-IL-4, anti-IL-7 receptor or anti-TNF antibodies had no effect on proliferation. Stimulation with CD2 + CD28 induced long-term autocrine (at least for IL-2) proliferation for CD4+ T cells, with no evidence for the implication of another cytokine among those tested other than IL-2. This represents a model for long-term autocrine growth for non-leukemic cells.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095456     DOI: 10.1002/eji.1830230304

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  7 in total

1.  Molecular characterization of U937-dependent T-cell co-stimulation.

Authors:  T J Stonehouse; V E Woodhead; P S Herridge; H Ashrafian; M George; B M Chain; D R Katz
Journal:  Immunology       Date:  1999-01       Impact factor: 7.397

2.  Disparate effects of phorbol esters, CD3 and the costimulatory receptors CD2 and CD28 on RANTES secretion by human T lymphocytes.

Authors:  Y Sotsios; P J Blair; J Westwick; S G Ward
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

3.  Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.

Authors:  Y D Korin; J A Zack
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

4.  Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.

Authors:  Sophie Reuse; Miriam Calao; Kabamba Kabeya; Allan Guiguen; Jean-Stéphane Gatot; Vincent Quivy; Caroline Vanhulle; Aurélia Lamine; Dolores Vaira; Dominique Demonte; Valérie Martinelli; Emmanuelle Veithen; Thomas Cherrier; Véronique Avettand; Solène Poutrel; Jacques Piette; Yvan de Launoit; Michel Moutschen; Arsène Burny; Christine Rouzioux; Stéphane De Wit; Georges Herbein; Olivier Rohr; Yves Collette; Olivier Lambotte; Nathan Clumeck; Carine Van Lint
Journal:  PLoS One       Date:  2009-06-30       Impact factor: 3.240

5.  Isolation and functional characterization of T cells from human sputum.

Authors:  G T Pang; R L Clancy; G E Reeves
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

6.  Interleukin-7 is a potent co-stimulus of the adhesion pathway involving CD2 and CD28 molecules.

Authors:  R Costello; H Brailly; F Mallet; C Mawas; D Olive
Journal:  Immunology       Date:  1993-11       Impact factor: 7.397

7.  First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Authors:  Olga Salamero; Pau Montesinos; Christophe Willekens; José Antonio Pérez-Simón; Arnaud Pigneux; Christian Récher; Rakesh Popat; Cecilia Carpio; César Molinero; Cristina Mascaró; Joaquim Vila; M Isabel Arévalo; Tamara Maes; Carlos Buesa; Francesc Bosch; Tim C P Somervaille
Journal:  J Clin Oncol       Date:  2020-10-14       Impact factor: 44.544

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.